Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 124

1.

Immunotherapy Resistance by Inflammation-Induced Dedifferentiation.

Mehta A, Kim YJ, Robert L, Tsoi J, Comin-Anduix B, Berent-Maoz B, Cochran AJ, Economou JS, Tumeh PC, Puig-Saus C, Ribas A.

Cancer Discov. 2018 Aug;8(8):935-943. doi: 10.1158/2159-8290.CD-17-1178. Epub 2018 Jun 13.

PMID:
29899062
2.

Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products.

Nowicki TS, Escuin-Ordinas H, Avramis E, Chmielowski B, Chodon T, Berent-Maoz B, Wang X, Kaplan-Lefko P, Yang L, Baltimore D, Economou JS, Ribas A, Comin-Anduix B.

J Immunother. 2018 Jun;41(5):248-259. doi: 10.1097/CJI.0000000000000216.

3.

Cancer Research in the 21st Century.

Economou JS, Slamon DJ, Ribas A, Phelps ME.

Ann Surg. 2016 Oct;264(4):555-65. doi: 10.1097/SLA.0000000000001926. No abstract available.

PMID:
27537535
4.

Engines of Discovery and Innovation.

Economou JS.

Ann Surg. 2016 Sep;264(3):405-12. doi: 10.1097/SLA.0000000000001876. No abstract available.

PMID:
27464615
5.

Gender bias in biomedical research.

Economou JS.

Surgery. 2014 Nov;156(5):1061-5. doi: 10.1016/j.surg.2014.07.005. Epub 2014 Sep 26. No abstract available.

PMID:
25262221
6.

Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients.

Butterfield LH, Economou JS, Gamblin TC, Geller DA.

J Transl Med. 2014 Apr 5;12:86. doi: 10.1186/1479-5876-12-86.

7.

Aberrant apoptotic machinery confers melanoma dual resistance to BRAF(V600E) inhibitor and immune effector cells: immunosensitization by a histone deacetylase inhibitor.

Jazirehi AR, Nazarian R, Torres-Collado AX, Economou JS.

Am J Clin Exp Immunol. 2014 Feb 27;3(1):43-56. eCollection 2014.

8.

Histone deacetylase inhibitor sensitizes apoptosis-resistant melanomas to cytotoxic human T lymphocytes through regulation of TRAIL/DR5 pathway.

Jazirehi AR, Kurdistani SK, Economou JS.

J Immunol. 2014 Apr 15;192(8):3981-9. doi: 10.4049/jimmunol.1302532. Epub 2014 Mar 17.

9.

Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma.

Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJ, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Daniels GA, Mukherji B, Yang L, Zack JA, Kohn DB, Heath JR, Glaspy JA, Witte ON, Baltimore D, Economou JS, Ribas A.

Clin Cancer Res. 2014 May 1;20(9):2457-65. doi: 10.1158/1078-0432.CCR-13-3017. Epub 2014 Mar 14.

10.

Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy.

Ma C, Cheung AF, Chodon T, Koya RC, Wu Z, Ng C, Avramis E, Cochran AJ, Witte ON, Baltimore D, Chmielowski B, Economou JS, Comin-Anduix B, Ribas A, Heath JR.

Cancer Discov. 2013 Apr;3(4):418-29. doi: 10.1158/2159-8290.CD-12-0383. Epub 2013 Mar 21.

11.

Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells.

Giannoni F, Hardee CL, Wherley J, Gschweng E, Senadheera S, Kaufman ML, Chan R, Bahner I, Gersuk V, Wang X, Gjertson D, Baltimore D, Witte ON, Economou JS, Ribas A, Kohn DB.

Mol Ther. 2013 May;21(5):1044-54. doi: 10.1038/mt.2013.8. Epub 2013 Feb 5.

12.

A society in transition: presidential remarks at the 65th Annual SSO Cancer Symposium.

Economou JS.

Ann Surg Oncol. 2012 Oct;19(11):3293-7. doi: 10.1245/s10434-012-2443-y. Epub 2012 Jul 18. No abstract available.

13.

T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFβ) signaling mediate superior tumor regression in an animal model of adoptive cell therapy.

Quatromoni JG, Wang Y, Vo DD, Morris LF, Jazirehi AR, McBride W, Chatila T, Koya RC, Economou JS.

J Transl Med. 2012 Jun 19;10:127. doi: 10.1186/1479-5876-10-127.

14.

Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs.

Jazirehi AR, Economou JS.

Mol Cancer Ther. 2012 Jun;11(6):1332-41. doi: 10.1158/1535-7163.MCT-11-0814. Epub 2012 Apr 24. Retraction in: Mol Cancer Ther. 2017 May;16(5):977.

15.

T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express foxp3.

Quatromoni JG, Morris LF, Donahue TR, Wang Y, McBride W, Chatila T, Economou JS.

J Hematol Oncol. 2011 Nov 23;4:48. doi: 10.1186/1756-8722-4-48.

16.

Immunomodulation by imiquimod in patients with high-risk primary melanoma.

Narayan R, Nguyen H, Bentow JJ, Moy L, Lee DK, Greger S, Haskell J, Vanchinathan V, Chang PL, Tsui S, Konishi T, Comin-Anduix B, Dauphine C, Vargas HI, Economou JS, Ribas A, Bruhn KW, Craft N.

J Invest Dermatol. 2012 Jan;132(1):163-9. doi: 10.1038/jid.2011.247. Epub 2011 Aug 18.

17.

CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.

Huang RR, Jalil J, Economou JS, Chmielowski B, Koya RC, Mok S, Sazegar H, Seja E, Villanueva A, Gomez-Navarro J, Glaspy JA, Cochran AJ, Ribas A.

Clin Cancer Res. 2011 Jun 15;17(12):4101-9. doi: 10.1158/1078-0432.CCR-11-0407. Epub 2011 May 10.

18.

Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction.

Jazirehi AR, Baritaki S, Koya RC, Bonavida B, Economou JS.

Cancer Res. 2011 Feb 15;71(4):1406-17. doi: 10.1158/0008-5472.CAN-10-1296. Epub 2010 Dec 15. Retraction in: Cancer Res. 2017 Jul 1;77(13):3718.

19.

Radiation enhances regulatory T cell representation.

Kachikwu EL, Iwamoto KS, Liao YP, DeMarco JJ, Agazaryan N, Economou JS, McBride WH, Schaue D.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1128-35. doi: 10.1016/j.ijrobp.2010.09.034. Epub 2010 Nov 17.

20.

MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro.

Ray S, Chhabra A, Chakraborty NG, Hegde U, Dorsky DI, Chodon T, von Euw E, Comin-Anduix B, Koya RC, Ribas A, Economou JS, Rosenberg SA, Mukherji B; UCLA-CALTECH-CHLA-USC-UCONN Consortium on Translational Program in Engineered Immunity.

Clin Immunol. 2010 Sep;136(3):338-47. doi: 10.1016/j.clim.2010.04.013. Epub 2010 May 23.

21.

Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824.

Vo DD, Prins RM, Begley JL, Donahue TR, Morris LF, Bruhn KW, de la Rocha P, Yang MY, Mok S, Garban HJ, Craft N, Economou JS, Marincola FM, Wang E, Ribas A.

Cancer Res. 2009 Nov 15;69(22):8693-9. doi: 10.1158/0008-5472.CAN-09-1456. Epub 2009 Oct 27.

22.

Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.

Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, McCannel TA, Ochoa MT, Seja E, Villanueva A, Oseguera DK, Straatsma BR, Cochran AJ, Glaspy JA, Hui L, Marincola FM, Wang E, Economou JS, Gomez-Navarro J.

Clin Cancer Res. 2009 Oct 1;15(19):6267-76. doi: 10.1158/1078-0432.CCR-09-1254. Epub 2009 Sep 29.

23.

Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade.

Ribas A, Comin-Anduix B, Economou JS, Donahue TR, de la Rocha P, Morris LF, Jalil J, Dissette VB, Shintaku IP, Glaspy JA, Gomez-Navarro J, Cochran AJ.

Clin Cancer Res. 2009 Jan 1;15(1):390-9. doi: 10.1158/1078-0432.CCR-08-0783.

24.

CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model.

Chhabra A, Yang L, Wang P, Comin-Anduix B, Das R, Chakraborty NG, Ray S, Mehrotra S, Yang H, Hardee CL, Hollis R, Dorsky DI, Koya R, Kohn DB, Ribas A, Economou JS, Baltimore D, Mukherji B.

J Immunol. 2008 Jul 15;181(2):1063-70.

25.

Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma.

Comin-Anduix B, Lee Y, Jalil J, Algazi A, de la Rocha P, Camacho LH, Bozon VA, Bulanhagui CA, Seja E, Villanueva A, Straatsma BR, Gualberto A, Economou JS, Glaspy JA, Gomez-Navarro J, Ribas A.

J Transl Med. 2008 May 1;6:22. doi: 10.1186/1479-5876-6-22.

26.

Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.

Butterfield LH, Comin-Anduix B, Vujanovic L, Lee Y, Dissette VB, Yang JQ, Vu HT, Seja E, Oseguera DK, Potter DM, Glaspy JA, Economou JS, Ribas A.

J Immunother. 2008 Apr;31(3):294-309. doi: 10.1097/CJI.0b013e31816a8910.

27.

Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer.

Butterfield LH, Ribas A, Potter DM, Economou JS.

Cancer Immunol Immunother. 2007 Dec;56(12):1931-43. Epub 2007 May 24.

PMID:
17522860
28.

Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma.

Straatsma BR, Nusinowitz S, Young TA, Gordon LK, Chun MW, Rosen C, Seja E, Economou JS, Glaspy JA, Bozon V, Gomez-Navarro J, Ribas A.

Am J Ophthalmol. 2007 Jun;143(6):958-969. Epub 2007 Apr 16.

PMID:
17434437
29.

NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain.

Prins RM, Vo DD, Khan-Farooqi H, Yang MY, Soto H, Economou JS, Liau LM, Ribas A.

J Immunol. 2006 Dec 15;177(12):8448-55.

30.

A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides.

Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, De la Rocha P, Duran SD, Hernandez J, Seja E, Potter DM, McBride WH, Finn R, Glaspy JA, Economou JS.

Clin Cancer Res. 2006 May 1;12(9):2817-25.

31.

Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade).

Schumacher LY, Vo DD, Garban HJ, Comin-Anduix B, Owens SK, Dissette VB, Glaspy JA, McBride WH, Bonavida B, Economou JS, Ribas A.

J Immunol. 2006 Apr 15;176(8):4757-65.

32.

Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays.

Comin-Anduix B, Gualberto A, Glaspy JA, Seja E, Ontiveros M, Reardon DL, Renteria R, Englahner B, Economou JS, Gomez-Navarro J, Ribas A.

Clin Cancer Res. 2006 Jan 1;12(1):107-16.

33.

Broad antitumor protection by dendritic cells administered to CD8alpha knock out mice.

Ribas A, Vo DD, Weeks DL, Comin-Anduix B, Schumacher LY, Garban HJ, McLean C, Yang J, Dissette VB, Peraza P, Owens SK, McBride WH, Glaspy JA, Economou JS.

Cancer Immunol Immunother. 2006 Jun;55(6):663-71. Epub 2005 Aug 13.

PMID:
16133107
34.

Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells.

Wargo JA, Schumacher LY, Comin-Anduix B, Dissette VB, Glaspy JA, McBride WH, Butterfield LH, Economou JS, Ribas A.

Cancer Gene Ther. 2005 Jun;12(6):516-27.

PMID:
15775996
35.

Antigen presentation by MART-1 adenovirus-transduced interleukin-10-polarized human monocyte-derived dendritic cells.

Mehrotra S, Chhabra A, Chakraborty A, Chattopadhyay S, Slowik M, Stevens R, Zengou R, Mathias C, Butterfield LH, Dorsky DI, Economou JS, Mukherji B, Chakraborty NG.

Immunology. 2004 Dec;113(4):472-81.

36.

Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy.

Ribas A, Glaspy JA, Lee Y, Dissette VB, Seja E, Vu HT, Tchekmedyian NS, Oseguera D, Comin-Anduix B, Wargo JA, Amarnani SN, McBride WH, Economou JS, Butterfield LH.

J Immunother. 2004 Sep-Oct;27(5):354-67.

PMID:
15314544
37.

Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma.

Gordon LK, Ribas A, Nusinowitz S, Butterfield LH, Glaspy JA, Economou JS, Straatsma BR.

Control Clin Trials. 2004 Aug;25(4):400-7.

PMID:
15296814
38.

Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells.

Liao YP, Wang CC, Butterfield LH, Economou JS, Ribas A, Meng WS, Iwamoto KS, McBride WH.

J Immunol. 2004 Aug 15;173(4):2462-9.

39.

Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses.

Schumacher L, Ribas A, Dissette VB, McBride WH, Mukherji B, Economou JS, Butterfield LH.

J Immunother. 2004 May-Jun;27(3):191-200.

PMID:
15076136
40.

Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells.

Ribas A, Wargo JA, Comin-Anduix B, Sanetti S, Schumacher LY, McLean C, Dissette VB, Glaspy JA, McBride WH, Butterfield LH, Economou JS.

J Immunol. 2004 Apr 15;172(8):4762-9.

41.

T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer.

Butterfield LH, Ribas A, Meng WS, Dissette VB, Amarnani S, Vu HT, Seja E, Todd K, Glaspy JA, McBride WH, Economou JS.

Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5902-8.

42.

Regulation of melanoma epitope-specific cytolytic T lymphocyte response by immature and activated dendritic cells, in vitro.

Mehrotra S, Stevens R, Zengou R, Chakraborty NG, Butterfield LH, Economou JS, Dorsky DI, Mukherji B.

Cancer Res. 2003 Sep 1;63(17):5607-14.

43.

Current developments in cancer vaccines and cellular immunotherapy.

Ribas A, Butterfield LH, Glaspy JA, Economou JS.

J Clin Oncol. 2003 Jun 15;21(12):2415-32. Review.

PMID:
12805342
44.

Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma.

Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, Wang HJ, Elashoff RM, McBride WH, Mukherji B, Cochran AJ, Glaspy JA, Economou JS.

Clin Cancer Res. 2003 Mar;9(3):998-1008.

45.

Determinant spreading and tumor responses after peptide-based cancer immunotherapy.

Ribas A, Timmerman JM, Butterfield LH, Economou JS.

Trends Immunol. 2003 Feb;24(2):58-61. Review.

PMID:
12547500
46.

The status of gene therapy for surgical disease.

Wargo JA, Economou JS.

Adv Surg. 2002;36:223-57. Review. No abstract available.

PMID:
12465553
47.

Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene-modified dendritic cell vaccines.

Ribas A, Amarnani SN, Buga GM, Butterfield LH, Dissette VB, McBride WH, Glaspy JA, Ignarro LJ, Economou JS.

Cancer Gene Ther. 2002 Nov;9(11):875-83.

48.

Cancer immunotherapy using gene-modified dendritic cells.

Ribas A, Butterfield LH, Glaspy JA, Economou JS.

Curr Gene Ther. 2002 Feb;2(1):57-78. Review.

PMID:
12108974
49.

CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells.

Ribas A, Butterfield LH, Amarnani SN, Dissette VB, Kim D, Meng WS, Miranda GA, Wang HJ, McBride WH, Glaspy JA, Economou JS.

Cancer Res. 2001 Dec 15;61(24):8787-93.

50.

alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination.

Meng WS, Butterfield LH, Ribas A, Dissette VB, Heller JB, Miranda GA, Glaspy JA, McBride WH, Economou JS.

Cancer Res. 2001 Dec 15;61(24):8782-6.

Supplemental Content

Loading ...
Support Center